NCT07015151

Mobile Lung Cancer Screening

Lyon Initiative for the Mobile Demedicalized Initiation of Lung Cancer Screening

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 4,312 (estimated)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 50 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Lung cancer screening using low-dose CT (LDCT) has been shown to reduce mortality in high-risk populations. In 2022, the French National Cancer Institute (INCa) issued guidelines recommending screening for individuals aged 50-74 with a history of heavy smoking, including current smokers or those who quit less than 15 years ago. A national pilot program (IMPULSION) will be launched in 2025. Lung cancer incidence is strongly correlated with socioeconomic status, yet underserved populations remain difficult to engage in screening programs. Mobile health units using a "reach-out" strategy have demonstrated effectiveness in other countries (UK, Brazil, USA). In France, this approach has been used for breast cancer screening via mobile mammography units. The MobILYAD project aims to compare two screening modalities- a mobile demedicalized unit (CT-equipped van with trained nurses) and a conventional hospital-based unit- to assess the effectiveness of mobile screening in reaching socially disadvantaged populations.

Conditions

• Lung Cancer Prevention

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Low-dose Chest CT Screening	Participants undergo a low-dose chest CT scan to screen for early lung cancer and assess associated conditions (emphysema, coronary calcifications, osteoporosis).
DIAGNOSTIC_TEST	Spirometry	Assessment of lung function through spirometry, with optional plethysmography and diffusion testing to detect COPD and PRISM patterns.
DIAGNOSTIC_TEST	Cardiovascular Risk Assessment	Cardiovascular risk is evaluated using SCORE2/SCORE2-OP tools, based on blood pressure and cholesterol levels.
BEHAVIORAL	Smoking Cessation Support	Active smokers receive a structured smoking cessation intervention, including a baseline consultation and up to two follow-up sessions (which may be remote).
OTHER	Optional Biospecimen Collection (Bio-ILYAD)	Optional collection of blood and exhaled breath condensate for future analysis of biomarkers in lung cancer detection.

Timeline

• Start date: 2025-06-12
• Primary completion: 2028-09-01
• Completion: 2028-09-01
• First posted: 2025-06-11
• Last updated: 2025-09-09

Locations

2 sites across 1 country: France